Mantle will use Ethereum blobs for data availability, moving from Validium toward a full Ethereum-secured ZK rollup while retaining EigenLayer integrations.Mantle will use Ethereum blobs for data availability, moving from Validium toward a full Ethereum-secured ZK rollup while retaining EigenLayer integrations.

Mantle Moves to Ethereum Blobs, Accelerating Path to Full ZK Rollup Security

mantle

Mantle, the high-performance distribution layer that connects traditional finance, real-world assets and on-chain liquidity, announced today that it will begin using Ethereum blobs as its primary data availability layer, a move the project says brings it one step closer to a full Ethereum ZK rollup architecture. The decision, framed by Mantle as a natural evolution of its security model, follows the recent Fusaka upgrades to Ethereum that expanded the protocol’s blob capacity and opened the door for rollups to post more data directly to L1.

For months, Mantle has operated with a Validium-style setup in certain respects, relying in part on off-chain DA to achieve low fees and latency. By settling rollup data on Ethereum blobs, Mantle will move toward a ZK rollup configuration that keeps transaction data verifiable and available on Ethereum’s settlement layer. The project frames this as a trade-up in security: the same low-cost, low-latency user experience, but with transaction data anchored more firmly to Ethereum’s base-layer guarantees.

Mantle’s timing reflects broader changes at the base layer. The Fusaka upgrade, which activated on mainnet in early December 2025, introduced improvements designed to increase blob throughput and make it easier for Layer 2 solutions to post larger volumes of data without prohibitive cost. Mantle’s announcement points to that increased capacity, which some implementations of Fusaka and subsequent parameter-only forks have multiplied, as the technical enabler that makes a production-scale, Ethereum-native ZK rollup on Mantle practical.

“This evolution is a natural progression for Mantle,” said Joshua Cheong, Head of Product of Mantle. “As Ethereum’s blob infrastructure matures through milestones like the Fusaka upgrade, we are now able to support production-scale applications with the full security of Ethereum’s data availability, without compromising on performance.” The company frames the change as a path to combine the strongest possible settlement guarantees with the sort of throughput and cost profile that attracts both developers and institutions.

From Validium to ZK Rollup

Mantle’s announcement also stresses that the move to blobs does not mean an abandonment of specialized tooling: the network will continue its close partnership with EigenLayer and will make use of EigenCloud for cases where verifiable compute and crypto-economic security provide unique benefits. Mantle said it will lean on EigenCloud for high-performance verticals such as perpetuals, prediction markets and AI agent infrastructure, and will deepen integrations around ecosystem shared security, including work tied to mETH and other restaking primitives. That balance, core DA on Ethereum blobs plus specialized services via EigenLayer, is how Mantle says it plans to capture both broad L2 security and specialized, high-assurance services.

The strategic pivot is also positioned as part of Mantle’s bid to become the on-ramp for institutions and TradFi into on-chain liquidity. With more than $4 billion in community-owned assets under its umbrella and an ecosystem anchored by $MNT and core projects such as mETH, fBTC and MI4, Mantle argues it can combine liquidity, credibility and institutional-grade infrastructure to support large-scale adoption. The project pointed to partnerships with established issuers and protocols, named in the announcement, as evidence of the kind of institutional relationships it is courting.

Technically, moving rollup data onto blobs simplifies the availability assumptions for dApps and wallets built on Mantle. Instead of relying on external DA committees or off-chain storage for data guarantees, developers will be able to point to Ethereum as the canonical source of posted data, which simplifies verification for light clients and aligns Mantle’s security model with the long-term Ethereum roadmap. Mantle described the shift as a way to “deliver the best possible experience for developers and end-users” while remaining actively involved with core contributors and modular partners across the ecosystem.

The broader industry will be watching whether Mantle’s hybrid approach, staking its core DA on Ethereum blobs while continuing to tap EigenCloud for compute and niche security properties, becomes a model other L2s emulate. For now, Mantle’s message is clear: as the base layer improves, Layer 2s can and should adapt, and doing so makes the platform more attractive to risk-averse institutional actors who require both scale and on-chain finality.

Mantle’s transition to Ethereum blobs marks a visible step toward a future in which L2s take fuller advantage of L1 advancements, and it underlines an ongoing theme in Ethereum’s roadmap: modular upgrades at the base layer can unlock new security and scalability trade-offs for the layers above. Mantle positions itself to capitalize on that dynamic as it continues to expand partnerships and product offerings for both retail and institutional participants.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26